How Biomarkers Associated with Clinical trial designs

Gavin Coney
Clarivate Analytics, UK

Abstract

Background: Precision medicine has proven to achieve success in treating cancers because it is ready-made to a patient’s specific needs. Due to this tradition approach to treatment, however, planning a clinical test for precision medicine is markedly tougher than more conventional treatments. Unlike traditional drugs and biologics, clinical test designs for precision medicine must consider patients’ variability in genes. As a result, biomarker use in precision medicine has been critical for outlining patient segments, selecting trial locations and measuring trial success.

Keywords: Multidisciplinary team, Palliative care, Palliative patients, Clinical trial designs

INTRODUCTION

Historically, precision medicine – and biomarkers – has focused on oncology, but recent drug development has sought to use this approach to other therapeutic areas. What can we learn from historic precision medicine trials to guide confident trial planning in other therapy areas? What can we learn from use of biomarkers in oncology trials? How has the utilization of biomarkers in non-oncology trials evolved? What does the longer term hold for the utilization of digital biomarkers in precision medicine?

In this paper, we glance to find out from past precision medicine trials to supply insights on:

• The history of biomarkers in oncology
• The evolution of biomarker use in non-oncology related diseases
• The way forward for digital biomarkers in precision medicine
• Site identification and selection supported site experience working with specific biomarkers
• Strategies for planning a precision medicine trial to extend chances of success

METHODOLOGY

We have utilised data from Cortellis Clinical Trials Intelligence to analyse data from over 400,000 trials from various therapy areas to ascertain how biomarkers are utilized in each of the phases of drug development. We’ll identify which sorts of biomarker are hottest and the way they’re getting used to trace efficacy, safety and patient selection.

We also will investigate how trial duration has changed over the years and if biomarkers have had any impact on the timelines. As a result, biomarker use in precision medicine has been critical for outlining patient segments, selecting trial locations and measuring trial success.

Historically, precision medicine – and biomarkers – has focused on oncology, but recent drug development has sought to use this approach to other therapeutic areas. What can we learn from historic precision medicine trials to guide confident trial planning in other therapy areas?

Result

We will identify which sorts of biomarker are hottest and the way they’re getting used to trace efficacy, safety and patient selection. We’ll also investigate how trial duration has changed over the years and if biomarkers have had any impact on the timelines.

Because of this tradition approach to treatment, however, planning a clinical test for precision medicine is markedly tougher than more conventional treatments. Unlike traditional drugs and biologics, clinical test designs for precision medicine must consider patients’ variability in genes. As a result, biomarker use in precision medicine has been critical for outlining patient segments, selecting trial locations and measuring trial success.
locations and measuring trial success. we’ve utilised data from Cortellis Clinical Trials Intelligence to analyse data from over 400,000 trials from various therapy areas to ascertain how biomarkers are utilized in each of the phases of drug development. we’ll identify which sorts of biomarker are hottest and the way they’re getting used to trace efficacy, safety and patient selection. we’ll also investigate how trial duration has changed over the years and if biomarkers have had any impact on the timelines.

**DISCUSSION**

Historically, precision medicine – and biomarkers – has focused on oncology, but recent drug development has sought to use this approach to other therapeutic areas. What can we learn from historic precision medicine trials to guide confident trial planning in other therapy areas? What can we learn from use of biomarkers in oncology trials? What can we learn from historic precision medicine trials to guide confident trial planning in other therapy areas?

**CONCLUSION**

Unlike traditional drugs and biologics, clinical test designs for precision medicine must consider patients’ variability in genes. As a result, biomarker use in precision medicine has been critical for outlining patient segments, selecting trial locations and measuring trial success. we’ve utilised data from Cortellis Clinical Trials Intelligence to analyse data from over 400,000 trials from various therapy areas to ascertain how biomarkers are utilized in each of the phases of drug development. we’ll identify which sorts of biomarker are hottest and the way they’re getting used to trace efficacy, safety and patient selection. we’ll also investigate how trial duration has changed over the years and if biomarkers have had any impact on the timelines. we’ll identify which sorts of biomarker are hottest and the way they’re getting used to trace efficacy, safety and patient selection. we’ll also investigate how trial duration has changed over the years and if biomarkers have had any impact on the timelines.

**References**


